Silence Therapeutics Plc American Depository Share
SLN Real Time Price USDRecent trades of SLN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in SLN holdings by institutional investors
Quarterly net insider trading by SLN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
SLN Estimated quarterly lobbying spending
SLN Revenue by Segment or Geography
New SLN patent grants
-
Patent Title: Products and compositions Sep. 10, 2024
-
Patent Title: Nucleic acids for inhibiting expression of tmprss6 and iron chelators Sep. 03, 2024
-
Patent Title: Nucleic acids for inhibiting expression of lpa in a cell Aug. 06, 2024
-
Patent Title: Products and compositions May. 21, 2024
-
Patent Title: Nucleic acid linked to a trivalent glycoconjugate Feb. 27, 2024
-
Patent Title: Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages Jan. 16, 2024
-
Patent Title: Nucleic acids for inhibiting expression of c3 in a cell Sep. 12, 2023
-
Patent Title: Interfering rna molecules Feb. 14, 2023
-
Patent Title: Sirnas with vinylphosphonate at the 5′ end of the antisense strand Jan. 24, 2023
-
Patent Title: Nucleic acids for inhibiting expression of lpa in a cell Nov. 15, 2022
-
Patent Title: Products and compositions Aug. 16, 2022
-
Patent Title: Nucleic acids for inhibiting expression of lpa in a cell May. 03, 2022
-
Patent Title: Further novel oligonucleotide-ligand conjugates Apr. 12, 2022
-
Patent Title: Products and compositions Nov. 16, 2021
-
Patent Title: Products and compositions May. 25, 2021
-
Patent Title: Nucleic acid linked to a trivalent glycoconjugate Feb. 09, 2021
-
Patent Title: Interfering rna molecules Sep. 15, 2020
-
Patent Title: Interfering rna molecules Jun. 25, 2019
-
Patent Title: Interfering rna molecules Jun. 18, 2019
-
Patent Title: Interfering rna molecules Apr. 23, 2019
-
Patent Title: Interfering rna molecules Oct. 17, 2017
-
Patent Title: Interfering rna molecules Oct. 17, 2017
-
Patent Title: Interfering rna molecules Oct. 10, 2017
-
Patent Title: Interfering rna molecules Sep. 12, 2017
-
Patent Title: Interfering rna molecules Jul. 04, 2017
-
Patent Title: Lipids, lipid complexes and use thereof Nov. 08, 2016
-
Patent Title: Means for inhibiting the expression of ang2 Oct. 04, 2016
-
Patent Title: Coated lipid complexes and their use Jul. 12, 2016
-
Patent Title: Interfering rna molecules Dec. 29, 2015
-
Patent Title: Use of vegfr1 as a biomarker Sep. 15, 2015
-
Patent Title: Lipids, lipid complexes and use thereof Sep. 08, 2015
-
Patent Title: Further use of protein kinase n beta Jul. 14, 2015
-
Patent Title: Interfering rna molecules Jan. 13, 2015
-
Patent Title: Coated lipid complexes and their use Oct. 07, 2014
-
Patent Title: Means for inhibiting the expression of ang2 Sep. 09, 2014
-
Patent Title: Lipids, lipid complexes and use thereof May. 27, 2014
-
Patent Title: Means for inhibiting the expression of orc-1 May. 13, 2014
-
Patent Title: Lipids, lipid complexes and use thereof Jan. 22, 2013
-
Patent Title: Interfering rna molecules Dec. 04, 2012
-
Patent Title: Means for inhibiting the expression of protein kinase 3 Jul. 31, 2012
-
Patent Title: Lipids, lipid complexes and use thereof Sep. 13, 2011
-
Patent Title: Interfering rna molecules Feb. 22, 2011
-
Patent Title: Further use of protein kinase n beta May. 11, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to SLN from public contracts
Recent insights relating to SLN
Recent picks made for SLN stock on CNBC
ETFs with the largest estimated holdings in SLN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $SLN stock a Buy, Sell, or Hold?
- What is the price target for $SLN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $SLN stock?
- Who owns the most shares of $SLN stock?
- What funds own $SLN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SLN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
- Address London, X0
- Market Cap 236.6 million
- Employees 116
- Industrial Classification Pharmaceutical Preparations